Gross Margin

Treace Medical reports a Q4 revenue dip despite surgeon growth, revealing a strategic shift to lower-priced kits and a challenging 2026 outlook.

Endeavour Silver saw record 2025 revenue from new mines but posted a $119M loss due to financial instruments, high costs, and rising security risks in Mexico.

The children's apparel giant posts strong Q4 sales, but steep tariff impacts and strategic spending lead to a forecast of declining earnings per share.

After a challenging year, InTest Corp. posts a strong Q4 rebound, driven by growth in non-semi markets. A robust backlog signals a promising 2026.

Facing huge losses and a China crackdown, crypto miner Intchains bets its future on a new staking platform and accumulating a massive ETH treasury.

The diagnostics firm topped revenue forecasts with explosive growth in core tests, navigating a net loss with a strategic pivot into new markets.

Facing a 5-day suspension for failures tied to the Jontay Porter scandal, PointsBet Canada is claiming human error while the AGCO calls it a systemic failure.

As Acorn preps its Q4 results, we look at the microcap's macro impact on grid reliability, cell towers, and the burgeoning smart energy market.

In its debut, Identy.io achieves top-tier NIST results, challenging industry giants with superior speed and accuracy for border and national security.

Stratasys' EcoVadis Gold Medal places it in the top 5% globally, signaling a major shift toward sustainable practices in the additive manufacturing industry.

Eos Energy reports record revenue and a fortified balance sheet, resolving 'going concern' doubts, but sets 2026 guidance below analyst expectations.

The hydration giant posts a 29% revenue jump to $6.7B in its first year, signaling a strong start, but focuses on fixing customer service snags.

Titan International beat expectations in Q4, driven by a 21% surge in its construction division, and now eyes a strong 2026 as OEM destocking ends.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

The therapy giant reports robust revenue growth and record patient visits, backed by major acquisitions and new 10-year hospital system alliances.

With a record $411M backlog and surging revenue, Redwire's strategic pivot to defense and space comes at a high cost. Can it turn growth into profit?

PROCEPT BioRobotics reports record Aquablation procedures but lowers 2026 revenue guidance, signaling a strategic shift for long-term profitability.

The biopharma company shatters records with 51% growth in its key drug, ASCENIV, and outlines a strategic overhaul aimed at long-term market dominance.

The ad-tech giant posted record revenue for 2025, but a weaker-than-expected forecast for early 2026 sent its stock tumbling. What's next?

MiMedx reports record 2025 sales and a $100M buyback, but faces a major challenge from new Medicare reimbursement rules set to disrupt the wound care market.